Kishnani, Priya S. http://orcid.org/0000-0001-8251-909X
Martos-Moreno, Gabriel Ángel
Linglart, Agnès
Petryk, Anna
Messali, Andrew
Fang, Shona
Rockman-Greenberg, Cheryl
Ozono, Keiichi
Högler, Wolfgang
Seefried, Lothar
Dahir, Kathryn M.
Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 12 September 2023
Accepted: 19 January 2024
First Online: 8 March 2024
Declarations
:
: The Global HPP Registry is sponsored by Alexion, AstraZeneca Rare Disease (Boston, MA, USA) and overseen by a scientific advisory board of clinical experts, including employees of Alexion. The protocol for the registry was approved by the institutional review board (or equivalent) at each participating site and is being conducted in accordance with European Medicines Agency Good Pharmacovigilance Practices, International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, and the Declaration of Helsinki. All patients or parent/legal guardians provided written informed consent and approval to release medical records for inclusion in the registry.
: Not applicable.
: PSK, KMD, GAMM, AL, CRG, KO, WH, and LS consult for/have received research funding/honoraria from Alexion, AstraZeneca Rare Disease. AP, AM, and SF are employees of and may own stock/options in Alexion, AstraZeneca Rare Disease. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.